Dupilumab: IL-4/IL-13 Receptor Antagonist for Atopic Diseases
Dupilumab (Dupixent) is a fully human monoclonal antibody that blocks the shared IL-4/IL-13 receptor alpha subunit (IL-4Rα), inhibiting signalling of both IL-4 and IL-13 — the key cytokines driving type 2 (Th2) inflammation.
Approved for moderate-to-severe atopic dermatitis, severe asthma with type 2 inflammation, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic oesophagitis, prurigo nodularis, and alopecia areata in adolescents/adults.
Mechanism of Action
Binds IL-4Rα, preventing IL-4 and IL-13 signalling via JAK1/TYK2 pathway. This reduces Th2-driven inflammation: decreased IgE production, reduced eosinophilia, improved skin barrier function, and reduced mucus hypersecretion.
Indications & Use
Moderate-to-severe AD (adults, adolescents ≥12 years, children ≥6 months), severe asthma (eosinophilic or steroid-dependent), CRSwNP, eosinophilic oesophagitis, prurigo nodularis, alopecia areata. Subcutaneous injection every 2 weeks (or monthly in some indications).
Dosage
AD adults: loading 600 mg SC (two 300 mg injections), then 300 mg every 2 weeks. Children 6–11 years (15–29 kg): 300 mg every 4 weeks. Asthma: 200 or 300 mg every 2 weeks. Self-injection with auto-injector or pre-filled syringe.
Side Effects
Common: injection site reactions, conjunctivitis (unique to dupilumab — affects ~10% of AD patients), nasopharyngitis. Rare: facial/neck dermatitis. Not associated with immunosuppression or increased infection risk (unlike systemic immunosuppressants).
Drug Interactions
Minimal pharmacokinetic interactions. Avoid live vaccines during treatment. During dose tapering of systemic corticosteroids in asthma/CRSwNP, adrenal insufficiency may unmask — taper gradually.
Contraindications
Hypersensitivity to dupilumab. Active helminth (parasitic) infections (IL-13 is important for anti-helminth immunity — treat before starting).
Frequently Asked Questions
Why does dupilumab cause conjunctivitis?
Conjunctivitis occurs in ~10% of atopic dermatitis patients on dupilumab. The exact mechanism is debated — possibly due to blockade of IL-4/IL-13 in conjunctival tissue affecting homeostasis. It is usually managed with topical cyclosporine or saline drops.
How quickly does dupilumab work for atopic dermatitis?
Many patients see significant improvement within 4–8 weeks. Peak efficacy is usually achieved by 16 weeks. Approximately 40–50% of adults achieve EASI-75 (75% reduction in eczema severity) by 16 weeks.
Can dupilumab be used in children?
Yes. Dupilumab is approved for atopic dermatitis in infants from 6 months of age, with age- and weight-based dosing. It is also approved for asthma from age 6 and CRSwNP/eosinophilic oesophagitis in adolescents ≥12 years.
References
- EMA Dupixent SPC 2024
- NICE TA851: Dupilumab for atopic dermatitis 2023
- Bachert C et al. NEJM 2019 (CRSwNP)
Medical Disclaimer: This information is for educational purposes only and does not replace professional medical advice.